StonvexLoading…
StonvexStonvexStonvexCore line items from RXST's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $30.89M | $134.48M | $101.87M | $71.53M |
Operating Income | $-17.83M | $-48.19M | $-36.85M | $-24.68M |
Net Income | $-15.88M | $-38.94M | $-29.79M | $-11.79M |
EPS (Diluted) | $-0.38 | $-0.95 | $-0.73 | $-0.49 |
Total Assets | $303.99M | $311.81M | $308.53M | $309.01M |
Total Liabilities | $36.70M | $36.13M | $32.56M | $31.00M |
Cash & Equivalents | $17.57M | $19.95M | $29.63M | $40.35M |
Free Cash Flow OCF − CapEx | $-11.65M | $-19.34M | $-17.09M | $-15.32M |
Shares Outstanding | 41.38M | 41.24M | 41.08M | 40.91M |